1. Zhang, Wei, Ruan, Xianhui, Li, Yaoshuang, Zheng, Xiangqian, Gao, Ming. 2022. KDM1A promotes thyroid cancer progression and maintains stemness through the Wnt/β-catenin signaling pathway. In Theranostics, 12, 1500-1517. doi:10.7150/thno.66142. https://pubmed.ncbi.nlm.nih.gov/35198054/
2. Ramírez-Ramírez, Ruth, Gutiérrez-Angulo, Melva, Peregrina-Sandoval, Jorge, Cerda-Camacho, Felipe de Jesús, Ayala-Madrigal, Maria de la Luz. 2019. Somatic deletion of KDM1A/LSD1 gene is associated to advanced colorectal cancer stages. In Journal of clinical pathology, 73, 107-111. doi:10.1136/jclinpath-2019-206128. https://pubmed.ncbi.nlm.nih.gov/31471467/
3. Clark, Erin A, Wu, Feizhen, Chen, Yirui, Fang, Rui, Shi, Yujiang G. . GR and LSD1/KDM1A-Targeted Gene Activation Requires Selective H3K4me2 Demethylation at Enhancers. In Cell reports, 27, 3522-3532.e3. doi:10.1016/j.celrep.2019.05.062. https://pubmed.ncbi.nlm.nih.gov/31216473/
4. Alejo, Salvador, Palacios, Bridgitte E, Venkata, Prabhakar Pitta, Brenner, Andrew J, Sareddy, Gangadhara R. . Lysine-specific histone demethylase 1A (KDM1A/LSD1) inhibition attenuates DNA double-strand break repair and augments the efficacy of temozolomide in glioblastoma. In Neuro-oncology, 25, 1249-1261. doi:10.1093/neuonc/noad018. https://pubmed.ncbi.nlm.nih.gov/36652263/
5. Maes, Tamara, Mascaró, Cristina, Tirapu, Iñigo, Castro-Palomino, Julio Cesar, Buesa, Carlos. 2018. ORY-1001, a Potent and Selective Covalent KDM1A Inhibitor, for the Treatment of Acute Leukemia. In Cancer cell, 33, 495-511.e12. doi:10.1016/j.ccell.2018.02.002. https://pubmed.ncbi.nlm.nih.gov/29502954/
6. Mircetic, Jovan, Camgöz, Aylin, Abohawya, Moustafa, Buchholz, Frank, Stange, Daniel E. 2023. CRISPR/Cas9 Screen in Gastric Cancer Patient-Derived Organoids Reveals KDM1A-NDRG1 Axis as a Targetable Vulnerability. In Small methods, 7, e2201605. doi:10.1002/smtd.202201605. https://pubmed.ncbi.nlm.nih.gov/36908010/
7. Liu, Ye, Chen, Yifang, Batzorig, Uyanga, Gallo, Richard L, Sen, George L. 2024. The transcription regulators ZNF750 and LSD1/KDM1A dampen inflammation on the skin's surface by silencing pattern recognition receptors. In Immunity, 57, 2296-2309.e5. doi:10.1016/j.immuni.2024.09.002. https://pubmed.ncbi.nlm.nih.gov/39353440/
8. Venkata, Prabhakar Pitta, Jayamohan, Sridharan, He, Yi, Vadlamudi, Ratna K, Sareddy, Gangadhara R. 2023. Pharmacological inhibition of KDM1A/LSD1 enhances estrogen receptor beta-mediated tumor suppression in ovarian cancer. In Cancer letters, 575, 216383. doi:10.1016/j.canlet.2023.216383. https://pubmed.ncbi.nlm.nih.gov/37714256/
9. Chasseloup, Fanny, Regazzo, Daniela, Tosca, Lucie, Occhi, Gianluca, Kamenický, Peter. . KDM1A genotyping and expression in 146 sporadic somatotroph pituitary adenomas. In European journal of endocrinology, 190, 173-181. doi:10.1093/ejendo/lvae013. https://pubmed.ncbi.nlm.nih.gov/38330165/
10. Del Blanco, Beatriz, Niñerola, Sergio, Martín-González, Ana M, Ruan, Yijun, Barco, Ángel. 2024. Kdm1a safeguards the topological boundaries of PRC2-repressed genes and prevents aging-related euchromatinization in neurons. In Nature communications, 15, 1781. doi:10.1038/s41467-024-45773-3. https://pubmed.ncbi.nlm.nih.gov/38453932/
智鼠故事 
